Senses

Prevent Blindness Offers Parents, Caregivers, and Educators, Free Resources to Help Keep Children's Eyes and Vision Healthy

Retrieved on: 
Tuesday, July 27, 2021
Ophthalmology, Vision, Light, Senses, Amblyopia, Refractive error, Visual impairment, Strabismus, Astigmatism, Myopia, Pediatric ophthalmology, Blurred vision

Without early detection and treatment, uncorrected vision disorders can impair child development, interfere with learning, and even lead to permanent vision loss.

Key Points: 
  • Without early detection and treatment, uncorrected vision disorders can impair child development, interfere with learning, and even lead to permanent vision loss.
  • Common vision problems in children include amblyopia (lazy eye), strabismus (crossed eyes), and refractive errors, such as myopia, hyperopia and astigmatism.
  • Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight.
  • Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America.

 Inova Health System Expands Adoption of NeurOptics’ Pupillometers in ICUs, Stroke Units and Emergency Departments

Retrieved on: 
Tuesday, July 20, 2021
Medical devices, Health, Hospitals, Practice Management, Other Health, Optical, Branches of biology, Neurological pupil index, Vision, Reflexes, Pupil, Light, Senses, Pupilometer, Pupillometry, Ophthalmology, Pupillary response, Pupillary light reflex, NeurOptics, Inova Health System, NEUROPTICS, INOVA HEALTH SYSTEM

Inova has implemented 135 devices in five hospitals across 20 critical care units and five emergency departments.

Key Points: 
  • Inova has implemented 135 devices in five hospitals across 20 critical care units and five emergency departments.
  • Automated infrared pupillometry using NeurOptics NPi Pupillometer provides nurses and clinicians with an objective assessment of the pupillary light reflex.
  • The NPi Pupillometer measures pupil size and reactivity, which is expressed numerically on the Neurological Pupil index (NPi).
  • Our mission is to provide world-class healthcare every time, every touch to each person in every community we have the privilege to serve.

Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery

Retrieved on: 
Monday, July 19, 2021
Vision, Eye, Light, Senses, Optics, Contact lenses, Ophthalmology, Bausch & Lomb, Corrective lenses, Intraocular lens, Lomb, Astigmatism

Ten of the presentations discuss the clinical performance of one or more of Bausch + Lomb's enVista, Crystalens and Trulign intraocular lens (IOL) platforms.

Key Points: 
  • Ten of the presentations discuss the clinical performance of one or more of Bausch + Lomb's enVista, Crystalens and Trulign intraocular lens (IOL) platforms.
  • Another poster will compare the refractive astigmatism prediction accuracy of Emmetropic Verifying Optical toric calculator.
  • Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries.
  • Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.

Worldwide Eye Care Industry to 2026 - Growing Prevalence of Different Ocular Problems is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Health, Optical, Vision, Ophthalmology, Light, Senses, Corrective lenses, Optometry, Far-sightedness, Myopia, Astigmatism, Contact lens, Intraocular lens, Glasses

The Global Eye Care Market stood at $57.65 billion in 2020 and is expected to witness a significant growth of 6.95% during the forecast period.

Key Points: 
  • The Global Eye Care Market stood at $57.65 billion in 2020 and is expected to witness a significant growth of 6.95% during the forecast period.
  • This can be attributed to the growing consciousness among the population pertaining to different eye diseases such as myopia, hypermetropia, dry eye syndrome, astigmatism, among others.
  • Also, growing prevalence of different ocular problems worldwide is further expected to fuel the market growth over the next few years.
  • Based on product type, the market can be categorized into eyeglasses, eye drops, contact lens, intraocular lens, eye vitamins and others.

Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021

Retrieved on: 
Wednesday, June 23, 2021
NicOx, Vision, Organ systems, Senses

Dr. Wirtas presentation will be available from June 30, 2021 on the website of the World Glaucoma E-Congress via a link dedicated to the E-posters.

Key Points: 
  • Dr. Wirtas presentation will be available from June 30, 2021 on the website of the World Glaucoma E-Congress via a link dedicated to the E-posters.
  • Nicoxs lead clinical development product candidate, NCX 470 is a novel NO-donating prostaglandin analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
  • Nicoxs lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.
  • The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.

Midwest Eye Care Announces The Return of Mission Cataract

Retrieved on: 
Friday, June 4, 2021
Ophthalmology, Vision, Light, Senses, Blindness, Cataract, Eye, Medicare

OMAHA, Neb., June 4, 2021 /PRNewswire/ -- After a hiatus in 2020 due to COVID-19, Midwest Eye Care is pleased to announce the return of Mission Cataract, in cooperation with Clarkson Family Medicine and the UNMC Department of Anesthesia.

Key Points: 
  • OMAHA, Neb., June 4, 2021 /PRNewswire/ -- After a hiatus in 2020 due to COVID-19, Midwest Eye Care is pleased to announce the return of Mission Cataract, in cooperation with Clarkson Family Medicine and the UNMC Department of Anesthesia.
  • "We are acutely aware of people in our area whose needs for eye health care are not covered by their own income or supplemental health plans such as Medicare, Medicaid, or other third-party payers," says Dr. David Ingvoldstad of Midwest Eye Care.
  • Potential candidates should contact Midwest Eye Care at 402.552.2020 for an application packet or go to www.midwesteyecare.com/mission-cataract to print the packet.
  • All paperwork must be received by Midwest Eye Care by June 18, 2021, to be considered for the surgery.

Vision Care Market Forecast to 2027: Focus on Eye Glasses, Contact Lens, Intraocular Lens, Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 1, 2021
Health, Optical, Corrective lenses, Vision, Light, Senses, Ophthalmology, Eye, Contact lens, Optometry, Intraocular lens, Cataract surgery, Laser blended vision

The growth of the market is mainly attributed to factors such Growing prevalence of eye diseases and rising funds for eye care research are driving the growth of the vision care market.

Key Points: 
  • The growth of the market is mainly attributed to factors such Growing prevalence of eye diseases and rising funds for eye care research are driving the growth of the vision care market.
  • Further, the increasing awareness about vision care offer significant opportunities for the growth of the global vision care market.
  • Extensive eye diseases research across the world to identify new treatments for the eye diseases is likely to favor the market growth.
  • Based on product type, the global vision care market is segmented into eye glasses, contact lens, intraocular lens, and others.

Ceyeber Successfully Completed the Enablement of Claims for US Patent 9,662,199 B2

Retrieved on: 
Monday, May 17, 2021
Marketing, Eye, Ophthalmology, Vision, Light, Senses, Intraocular lens, Enablement, Augmented reality, IOL, Patent

b'NEWPORT BEACH, Calif., May 17, 2021 /PRNewswire/ -- Ceyeber has appointed Kyle Webb as the Director of Research and Development.

Key Points: 
  • b'NEWPORT BEACH, Calif., May 17, 2021 /PRNewswire/ -- Ceyeber has appointed Kyle Webb as the Director of Research and Development.
  • In 2018, Webb began the planning and development processes that resulted in the embodiment of a benchtop working embodiment of Ceyeber US Patent No.
  • Webb completed his Bachelor of Science in Mechanical Engineering & Technology and has multiple publications in Ophthalmology journals on small-aperture IOL devices.
  • "\nWith the successful enablement of claims in the patent, Ceyeber is enthusiastically looking to the future as the patent is brought to life.\nCeyeber is the developer of implantable intraocular lens technology designed for medical applications and augmented reality.

FDA-approved contact lenses to slow myopia progression in children

Retrieved on: 
Tuesday, May 11, 2021
Vision, Ophthalmology, Health, Senses, Disability, Near-sightedness, Corrective lenses, Retinal detachment, Optometry, Contact lens, Eye disease, Macular Society

This number is increasing at an alarming rate, especially among school-age children.\nMyopic children have higher chances of developing high myopia (a severe form of myopia).

Key Points: 
  • This number is increasing at an alarming rate, especially among school-age children.\nMyopic children have higher chances of developing high myopia (a severe form of myopia).
  • Patients with high myopia are prone to develop sight-threatening eye conditions such as cataracts, glaucoma, retinal detachment, and macular degeneration among other eye diseases.\nTo avoid sight-threatening eye conditions, myopia should be treated early.
  • Optometrists who practice myopic control can help curb kids\' myopia starting as early as age 7 and up.\n"MiSight multifocal contact lenses address the axial length, which is a core problem of myopia," says Dr.
  • "\nIntroducing myopic control at Eyepic Eye Care will help our communities understand the long-term effects of myopia and offer them a solution to slow its progression in children.

LENSAR to Hold First Quarter 2021 Financial Results Conference Call on Wednesday, May 5, 2021

Retrieved on: 
Wednesday, April 28, 2021
Optical, Health, Surgery, Medical devices, Vision, Light, Senses, Blindness, Cataract, Eye, Ophthalmology

b'LENSAR, Inc. (NASDAQ: LNSR) (\xe2\x80\x9cLENSAR\xe2\x80\x9d or \xe2\x80\x9cthe Company\xe2\x80\x9d), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company\xe2\x80\x99s first quarter 2021 financial results will be released before market open on Wednesday, May 5, 2021.

Key Points: 
  • b'LENSAR, Inc. (NASDAQ: LNSR) (\xe2\x80\x9cLENSAR\xe2\x80\x9d or \xe2\x80\x9cthe Company\xe2\x80\x9d), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company\xe2\x80\x99s first quarter 2021 financial results will be released before market open on Wednesday, May 5, 2021.
  • LENSAR\xe2\x80\x99s management will host a conference call and webcast at 8:30 am ET on Wednesday, May 5, 2021 to discuss the financial results and recent corporate highlights.\nTo participate by telephone, please dial (844) 200-6205 (Domestic) or (646) 904-5544 (International).
  • The conference ID number is 760694.
  • To access the live webcast, please go to the Investors section of LENSAR\xe2\x80\x99s website at www.lensar.com .